Legionnaires' disease is the most common atypical pneumonia disease in the world which is caused by a bacteria called legionella pneumophila. Given our cutting edge vaccine formulation strategies as well as our broad therapeutic approaches, we have confidence in our abilities to offer such solutions.
Introduction to Legionnaires' Disease
Legionnaires' illness, a critical type of bronchopneumonia, is thought to be caused chiefly by Legionella Pneumophila, a kind of bacteria which is aerobic, does not stain, and mostly gets formed in warm water sources. This bacterium occurs in stagnant water areas and can undergo mists, which can then be turned into micrometers that end up being inhaled, eventually causing a person lung infections that can be fatal.
Fig.1 Constructed vaccine figure with adjuvants and linkers. (Umar A., et al., 2022)
Vaccine Development for Legionnaires' Disease
Development of multiepitope vaccines is a current aim in medicine and scientists are actively conducting research toward this goal. Since there are no licensed vaccines against Legionnaires' disease, efforts have been made by the researchers like implementation of immunoinformatics and subtractive proteomics.
Immunoinformatics Approach
Immunoinformatics aids greatly in predicting B and T cell epitopes from promising proteins for a vaccine candidate. It also makes use of bioinformatics tools to expedite the identification of antigenic epitopes, thus refining the choice of protein for further vaccine development.
Multiepitope Vaccine Design
The multiepitope-based vaccine (MEBV) is designed to form CTL (cytotoxic T lymphocyte), HTL (helper T lymphocyte) and LBL (B lymphocyte) epitopes into a single structure with a high antigenic and immunogenic potential.
Therapeutics Development for Legionnaires' Disease
Legionnaires' disease is best treated with fluoroquinolones, azithromycin, and doxycycline. However, it is worth noting that the main challenge in combating this disease is the growing concern over antibiotic resistance, which makes necessary the development of new drugs altogether. If we extrapolate previous studies, it appears that the most effective combination of Legionnaires' disease therapy is a combination of macrolides and quinolones, but only when the condition is serious enough.
Our company provides great therapeutic strategy development for legionnaires' disease and has an amazing platform for it too. To read further, click the link down below.
Our Services
Given our comprehensive understanding, existing technologies, and innovative ambition, we are certain that we will achieve significant developments in the prevention and treatment of this lethal disease within the lungs. We specialize in everything concerning drugs and vaccine development from preclinical formulations to animal testing and translational research.
- Guinea Pig Models: injection of homogenized human lung samples into the peritoneum of guinea pigs
- Mouse Models: a strain mice (A/J) or genetically modified mice
Our research infrastructure is advanced and is well staffed with requisite skills aimed at developing Legionnaires' Disease drugs and vaccines. Should you be interested in engaging our services please do not hesitate to contact us for a comprehensive price quote along with other much needed details.
References
- Umar Ahitsham, et al. "Vaccinomics to Design a Multiepitope Vaccine against Legionella pneumophila." BioMed Research International 2022.1 (2022): 4975721.
- Viasus Diego, et al. "Legionnaires' disease: update on diagnosis and treatment." Infectious Diseases and Therapy 11.3 (2022): 973-986.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
